Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in
hematological malignancies that potentially circumvents many constraints of existing small …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating
proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have …

Chemical modulation of proteins enables a mechanistic understanding of biology and
represents the foundation of most therapeutics. However, despite decades of research, 80 …

Targeted protein degradation with proteolysis targeting chimeras (PROTACs) is a powerful
therapeutic modality for eliminating disease-causing proteins through targeted ubiquitination …

The nucleus controls cell growth and division through coordinated interactions between
nuclear proteins and chromatin. Mutations that impair nuclear protein association with …

Targeted protein degradation with monovalent molecular glue degraders is a powerful
therapeutic modality for eliminating disease causing proteins. However, rational design of …

Targeted protein degradation (TPD) represents a potent chemical biology paradigm that
leverages the cellular degradation machinery to pharmacologically eliminate specific …

Ubiquitination is an essential process that curtails cellular levels of damaged and redundant
proteins. Chemical biologists have harnessed this natural system to induce the degradation …

Proteolysis targeting chimera (PROTACs) provide a novel therapeutic approach that is
revolutionizing drug discovery. The success of PROTACs largely depends on the …